Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alzamend Neuro ( (ALZN) ) has provided an announcement.
On May 8, 2025, Alzamend Neuro announced a one-for-nine reverse stock split of its common stock to be effective on May 12, 2025, as part of its strategy to maintain compliance with Nasdaq’s minimum bid price requirement. The reverse stock split will affect all issued and outstanding shares and stock options, with no fractional shares issued, and aims to enhance the company’s market positioning and shareholder value.
More about Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company is working on two therapeutic drug candidates, AL001 and ALZN002, both licensed from the University of South Florida Research Foundation.
Average Trading Volume: 406,624
Technical Sentiment Signal: Sell
Current Market Cap: $4.2M
For detailed information about ALZN stock, go to TipRanks’ Stock Analysis page.